Plain-English translation of NCT06509126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a targeted cancer medication, combined with chemotherapy (FOLFIRI) for people with advanced colorectal cancer that started on the left side of the colon. The study compares two approaches: giving the medication without stopping, or giving it in cycles with breaks in between. The goal is to see which approach works better and is easier for patients to tolerate.
This medication has shown promise in treating this type of colorectal cancer, but doctors don't yet know if patients do better by taking it continuously or by taking breaks between treatment cycles. This trial will help answer that question and may make treatment more manageable for future patients.
You likely qualify if…
You likely don't qualify if…
You will start with an induction phase where all patients receive the targeted medication and chemotherapy together for up to 8 cycles (about 4 months), given intravenously every two weeks. Then you will be randomly assigned to one of two groups: the continuous group will keep receiving the medication until the cancer progresses, or the intermittent group will take breaks between treatment cycles and restart only if the cancer begins to grow again. Throughout the trial, you will have regular clinic visits and scans to monitor how your cancer is responding.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Italy